Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 30;29(1):14.
doi: 10.1186/s10020-023-00600-1.

Evaluation of inherited germline mutations in cancer susceptibility genes among pancreatic cancer patients: a single-center study

Francesca Tavano  1 , Domenica Gioffreda  2 , Andrea Fontana  3 , Orazio Palmieri  2 , Annamaria Gentile  2 , Tiziana Latiano  2 , Anna Latiano  2 , Tiziana Pia Latiano  4 , Matteo Scaramuzzi  5 , Evaristo Maiello  4 , Francesca Bazzocchi  5 , Francesco Perri  2
Affiliations

Evaluation of inherited germline mutations in cancer susceptibility genes among pancreatic cancer patients: a single-center study

Francesca Tavano et al. Mol Med. .

Abstract

Background: Germline mutations in cancer susceptibility genes were identified in pancreatic cancer (PanC) patients with a sporadic disease and in those unselected for family cancer history.

Methods: With the aim to determine the prevalence of germline predisposition genes mutations in PanC, and to evaluate whether they were associated with the presence of PanC, we profiled a custom AmpliSeq panel of 27 cancer susceptibility genes in 47 PanC patients and 51 control subjects by using the Ion Torrent PGM system.

Results: Multigene panel testing identified a total of 31 variants in 27 PanC (57.4%), including variants with pathogenic/likely pathogenic effect, those of uncertain significance, and variants whose clinical significance remains currently undefined. Five patients carried more than one variant in the same gene or in different genes. Eight patients (17.0%) had at least one pathogenic/likely pathogenic variant in four main genes: CFTR (10.6%), BRCA2 (8.5%), ATM and CHEK2 (2.1%). Pathogenic/likely pathogenic mutation were identified in patients with positive PanC family history (20%) or in patients without first-degree relatives affected by PanC (13.6%). All the BRCA2 mutation carriers were unselected PanC patients. The presence of mutations in BRCA2 was significantly associated with an increased occurrence of PanC and with positive family history for endometrial cancer (p = 0.018).

Conclusions: This study confirmed the potential remarkable contribution of BRCA2 in assessing the presence of PanC. Overall our findings supported the recommendation of offering the germline testing to all the PanC patients with the intent to reduce the number of underdiagnosed carriers of mutations in predisposition genes, and not to preclude their relatives from the opportunity to benefit from surveillance programs.

Keywords: Cancer family history; Genetic testing; Germline variants; Next Generation Sequencing; Pancreatic cancer; Prevalence.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1
Fig. 1
Genes with germline mutations in patients with pancreatic cancer (PanC)
See this image and copyright information in PMC

References

    1. Al-Sukhni W, Borgida A, Rothenmund H, Holter S, Semotiuk K, Grant R, et al. Screening for pancreatic cancer in a high-risk cohort: an eight-year experience. J Gastrointest Surg. 2012;16(4):771–783. doi: 10.1007/s11605-011-1781-6. - DOI - PubMed
    1. Al-Sukhni W, Aronson M, Gallinger S. Hereditary colorectal cancer syndromes: familial adenomatous polyposis and lynch syndrome. Surg Clin North Am. 2008;88(4):819–844. doi: 10.1016/j.suc.2008.04.012. - DOI - PubMed
    1. American Cancer Society. Key statistics for pancreatic cancer. [American Cancer Sociaty About pancreatic Cancer website]. http://www.cancer.org/cancer/pancreatic-cancer/about/key-statistics.html. Accessed 4 Sep 2018.
    1. Astiazaran-Symonds E, Goldstein AM. A systematic review of the prevalence of germline pathogenic variants in patients with pancreatic cancer. J Gastroenterol. 2021;56(8):713–721. doi: 10.1007/s00535-021-01806-y. - DOI - PMC - PubMed
    1. Barbari SR, Shcherbakova PV. Replicative DNA polymerase defects in human cancers: consequences, mechanisms, and implications for therapy. DNA Repair. 2017;56:16–25. doi: 10.1016/j.dnarep.2017.06.003. - DOI - PMC - PubMed

Publication types